He said he expects Valeant’s shares will recover in the coming years as its core business continues to prosper. “I still think the company is undervalued; that hasn’t changed”. Valeant is facing multiple federal investigations over issues surrounding patient assistance, drug pricing and market fairness. He also said he had visited Valeant’s headquarters to give employees a “pep talk”.
Advertisement
AbbVie said its wholly owned Pharmacy Solutions business aims to help patients and doctors verify insurance coverage in certain instances for drugs such as its widely-used rheumatoid arthritis treatment Humira. “There are a lot of people in the pharma sector who don’t like” Valeant CEO Mike Pearson, Ackman said.
A few other drug makers have said they own their own pharmacies. More information about Valeant can be found at www.valeant.com.
After seeing its stock price soar, Valeant Pharmaceuticals of Canada is now under pressure and its shares are down more than 60 percent. In fact, Express Scripts is now evaluating four additional specialty pharmacies with which Valeant has similar tie-ups.
In 2014, UnitedHealth Group conducted an inspection of Philidor and started cutting ties with the company “in the interests of our customers”.
Reitz now finds himself at the center of the national scandal enveloping Valeant Pharmaceuticals global, the once highflying Wall Street darling that in recent weeks had its stock price nearly cut in half.
Ackman, meanwhile, toiled in vain in the company’s defense in a specially convened conference call. In the year following each downgrade, Valeant surged 90% on average. Philidor would also not confirm Valeant’s assertion that it will cease operations.
This May 27, 2013 photo shows signage at Valeant Pharmaceutical’s headquarters in Montreal. For years doctors and insurers have condemned the runaway cost of prescription drugs. In practice, Valeant’s secret sauce has been to buy up companies, slash their staffs and research budgets, find clever ways to jack up prices and tap into the parent company’s rock-bottom corporate tax rate structure.
After the report, Valeant acknowledged that it held a major stake in Philidor and had an option to buy the company. Such an arrangement is rare in the industry. “We understand that patients, doctors, and business partners have been disturbed by the reports of improper behavior at Philidor, just as we have been”, Pearson said.
“You feel like a fool as the stock price goes up and up”, said the 38-year-old analyst, who told clients to get rid of Valeant shares after he became concerned about its accounting practices. That’s no longer the case.
The allegations of impropriety – which emerged last week – included claims Valeant was using Philidor and other “captive” pharmacies “for the objective of phantom sales or stuff the channel, and avoid scrutiny from the auditors”. Valeant has denied the accusations.
It seems Valeant’s insistence earlier this week that its relationship with specialty pharmacy Philidor was above board failed to convince pharmacy benefit managers. CVS cited “noncompliance” with its provider agreement with the pharmacy.
Advertisement
He also confirmed that the company recently purchased 2.1 million Valeant shares. He said the stock will reach US$448 by 2018, more than 70 per cent above its all-time high on August 5.
